A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection
in unresectable HCC patients.
This study plans to enroll 9 patients to assess the safety of C-TCR055. Subjects who meet the
eligibility criteria will receive a single dose of C-TCR055 injection, and will be followed
up post treatment for safety monitoring. The follow up period will last 12 months.
1. Able to provide written informed consent.
2. Age 18-70 years old, male or female.
3. Patients must meet the following criteria:
1. Histologically confirmed HCC
2. Serum AFP >200 ng/mL
3. Child-Pugh score ≤6
4. BCLC stage B and stage C or stage Ⅱa/Ⅱb and Ⅲa/Ⅲb defined by Chinese Liver Cancer
5. Clinical confirmed relapse or progression if patient had locoregional therapy
6. Systemic therapy failed HCC Subject: those who received standardized systemic
treatment for unresectable HCC and subsequently relapsed/progressed, or were
intolerable or unwilling to receive treatment.
7. Local treatment (including surgery, ablation, interventional therapy, local
radiotherapy, etc.) must be completed at least 4 weeks before apheresis, and
there is no unhealed wound.
8. Previous systemic therapy was discontinued at least 2 weeks before apheresis.
4. Has at least 1 measurable lesion as defined per RECIST v1.1.
5. HLA-A0201 allele positive.
6. Liver AFP expression IHC tests:
1. >=20% tumor cells positive, and <=5% non-tumor tissue positive;
2. serum AFP >=400ng/ml, and <=5% non-tumor tissue positive.
7. Laboratory criteria:
1. Absolute neutrophil count (ANC) ≥ 1.5x10^9/ L
2. Platelets≥ 60x10^9/L
3. Hemoglobin≥ 90g/L
4. Serum total bilirubin ≤ 2 x ULN
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 x ULN
6. Creatinine ≤1.5×ULN
7. International normalized ratio (INR) or prothrombin time (PT) ≤1.5 x ULN
8. ECOG score ≤ 1.
9. Left ventricular ejection fraction (LVEF) ≥ 50% (measured by echocardiography).
10. No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92%
on room air.
11. Expected survival > 12 weeks.
12. If patient has previous HBV infection, patient should receive antivirals treatment
following treatment guidelines during study period, and the HBV DNA copies should
below the detection limit at screening.
13. Female subjects in childbearing age, their serum or urine pregnancy test must be
negative, all subjects must agree to take effective contraceptive measures during the
1. Have a history of allergy to cellular products.
2. Subject has liver transplantation history.
3. Medium to severe ascites.
4. Subject has other primary cancer except for the following:
A. Non-melanoma cured by excision, such as basal cell skin cancer. B. Cured in situ
cancers such as cervical cancer, bladder cancer or breast cancer
5. Significant clinical gastrointestinal bleeding within 4 weeks before treatment.
6. Subjects with bone metastasis or central nervous system metastasis, or with hepatic
encephalopathy, epilepsy, cerebrovascular accident and other central nervous system
7. Prior treatment with genetically modified T cell therapy or stem cell therapy.
8. Uncontrolled active infection. Preventive antibiotics, antiviral and antifungal are
9. Active hepatitis virus infection. HCV RNA positive.
10. Subjects with syphilis or other acquired, congenital immunodeficiency disorders,
including, but not limited to, HIV infected persons, systemic lupus erythematosus,
11. Heart insufficiency subjects of Grade III or IV according to NYHA classification
12. Any other disease that may increase the risk of the subject or interfere with the
results of the study.